Approval · Notice of Compliance 14831 · 2013
FOSAMAX: Notice of Compliance 14831
Issued October 21, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14831
- Date
- October 21, 2013
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the following sections of the product monograph due to the discontinuation of the 40 mg tablet and 70 mg/ 70ml oral solution summary product information, indications and clinical use, adverse reactions, action and clinical pharmacology, dosage forms, composition and packaging, clinical trials, and part III consumer information
- Therapeutic class
- Bone metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FOSAMAX | Not yet assigned | — |
Medicinal ingredients
- ALENDRONIC ACID 70 MG per TAB